<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">Colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>), which frequently <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasizes</z:e> to the liver, is one of the three leading causes of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>-related <z:hpo ids='HP_0011420'>deaths</z:hpo> worldwide </plain></SENT>
<SENT sid="1" pm="."><plain>Growing evidence suggests that a subset of cells exists among <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> stem cells </plain></SENT>
<SENT sid="2" pm="."><plain>This distinct subpopulation is thought to contribute to <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastasis</z:e>; however, it has not been fully explored in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> yet </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: Flow cytometry analysis was performed to detect distinct subsets with CD133 and CXCR4 markers in human primary and metastatic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> tissues </plain></SENT>
<SENT sid="4" pm="."><plain>The 'stemness' and metastatic capacities of different subpopulations derived from the <z:hpo ids='HP_0003003'>colon cancer</z:hpo> cell line HCT116 were compared in vitro and in vivo </plain></SENT>
<SENT sid="5" pm="."><plain>The roles of epithelial-mesenchymal transition (EMT) and stromal-cell derived factor-1 (SDF-1) in the metastatic process were also investigated </plain></SENT>
<SENT sid="6" pm="."><plain>A survival curve was used to explore the correlation between the content of CD133(+)CXCR4(+) <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells and patient survival </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: In human specimens, the content of CD133(+)CXCR4(+) cells was higher in <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastases</z:e> than in primary <z:e sem="disease" ids="C0009404" disease_type="Neoplastic Process" abbrv="">colorectal tumors</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>Clonogenic and tumorigenic cells were restricted to CD133(+) cells in the HCT116 cell line, with CXCR4 expression having no impact on the 'stemness' properties </plain></SENT>
<SENT sid="9" pm="."><plain>We found that CD133(+)CXCR4(+)<z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells had a high metastatic capacity in vitro and in vivo </plain></SENT>
<SENT sid="10" pm="."><plain>Compared with CD133(+)CXCR4(-) cells, CD133(+)CXCR4(+)<z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells experienced EMT, which contributed partly to their metastatic phenotype </plain></SENT>
<SENT sid="11" pm="."><plain>We then determined that SDF-1/CXCL12 treatment could further induce EMT in CD133(+)CXCR4(+)<z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells and enhance their invasive behavior, while this could not be observed in CD133(+)CXCR4- <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells </plain></SENT>
<SENT sid="12" pm="."><plain>Blocking SDF-1/CXCR4 interaction with a CXCR4 <z:chebi fb="68" ids="48706">antagonist</z:chebi>, AMD3100 (1,10-[1,4-phenylenebis(<z:chebi fb="13" ids="29357,29358">methylene</z:chebi>)]bis-1,4,8,11 -tetraazacyclotetradecane octahydrochloride), inhibited <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastatic tumor</z:e> growth in a mouse <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">hepatic metastasis</z:e> model </plain></SENT>
<SENT sid="13" pm="."><plain>Finally, a high percentage of CD133(+)CXCR4(+)cells in human primary <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> was associated with a reduced two-year survival rate </plain></SENT>
<SENT sid="14" pm="."><plain>CONCLUSIONS: Strategies targeting the SDF-1/CXCR4 interaction may have important clinical applications in the suppression of <z:hpo ids='HP_0003003'>colon cancer</z:hpo> <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> </plain></SENT>
<SENT sid="15" pm="."><plain>Further investigations on how high expression of CXCR4 and EMT occur in this identified <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> stem cell subset are warranted to provide insights into our understanding of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> biology </plain></SENT>
</text></document>